Back to search results

CYAD-101 and Pembrolizumab for Metastatic Colorectal Cancer

This study is looking at a new treatment approach for people with metastatic colorectal cancer that cannot be removed by surgery. It combines CYAD-101, a type of cell therapy, with standard chemotherapy called FOLFOX (5-FU, leucovorin, and oxaliplatin), followed by another drug called Pembrolizumab. Researchers want to see how safe this combination is and if it can shrink tumors. You might be able to join if you have this type of cancer and your tumor is not 'microsatellite instability high' (non-MSI-H). The study will look at side effects and how many people respond to the treatment within about three months. The study plans to enroll 34 participants, but its current status is unclear.

Study design
This is an interventional study, meaning participants will receive specific treatments. It plans to enroll 34 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study measures responses up to 94 days after the first treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04991948

Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer

Recruiting
PHASE1Ages 18+InterventionalTreatment
Celyad Oncology SA
~34 participants
Updated 2022-03-09 on ClinicalTrials.gov
What's tested:CYAD-101FOLFOXPembrolizumab

At a glance

Recruiting sites
2 of 5 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The Occurrence of Dose Limiting Toxicities (DLT) during the 'DLT reporting period'
Measured over Up to 73 days post first study treatment administration
+1 more outcome measured

Conditions

Unresectable Metastatic Colorectal Cancer

Explore related trials

Colorectal CarcinomaMRC1 wt AlleleMSI1 Gene

Where it's being run

5 sites across 2 states
Belgium3
Florida2

Who to contact

Celyad Oncology Medical Monitor, MD, PhD
[email protected]
+3210394100
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • The Occurrence of Dose Limiting Toxicities (DLT) during the 'DLT reporting period'Up to 73 days post first study treatment administration

    The occurrence of DLT during the 'DLT reporting period' is defined as the period from study enrollment on D1 (Visit 1) up to 3 weeks after first pembrolizumab treatment on D73 (Visit 14).

  • The objective response rate (ORR) at the tumor assessment on Day 94 [Visit 15])Up to 94 days post first study treatment administration

    The objective response rate (ORR) at the tumor assessment on Day 94 \[Visit 15\]), 6 weeks after the first pembrolizumab treatment administration.